Abstract
Adalimumab is the only FDA- and EMA-approved treatment for moderate to severe hidradenitis suppurativa (HS), where etanercept and certolizumab-pegol have been shown to be inefficacious, suggesting that the mechanism of action (MOA) of adalimumab is distinct in HS and may contribute to improved wound healing. We have demonstrated that adalimumab, but neither etanercept nor certolizumab-pegol, induces a wound healing profile in vitro by regulating macrophage differentiation and matrix metalloproteinase expression which may underlie the difference in efficacy between various anti-TNF agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
